Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4213329 | 0.77 | PTGS2 (0.85) | PTGS2PTGS1 | |
| SCHEMBL5204977 | 0.76 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL5208636 | 0.76 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL5207098 | 0.76 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL5203543 | 0.76 | PTGS2 (0.83) | PTGS2PTGS1 | |
| SCHEMBL5203049 | 0.75 | PTGS2 (0.63) | PTGS2PTGS1 | |
| SCHEMBL6957905 | 0.75 | PTGS2 (0.73) | PTGS2PTGS1 | |
| SCHEMBL6957455 | 0.75 | PTGS2 (0.73) | PTGS2PTGS1 | |
| SCHEMBL5205472 | 0.75 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL6964255 | 0.75 | PTGS2 (0.73) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1061908-A4 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | MERCK & CO INC (US) | 2007-01-24 | — | — | EP | claimed |
| EP-1024696-A4 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIO- AND CEREBROVASCULAR DISEASE | MERCK & CO INC (US) | 2004-07-14 | — | — | EP | claimed |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | BOYCE SUSAN (GB) | 2004-05-20 | — | — | US | claimed |
| EP-1283723-A2 | COMBINATION THERAPY USING COX-2 SELECTIVE INHIBITOR AND THROMBOXANE INHIBITOR AND COMPOSITIONS THEREFOR | Merck Frosst Canada & Co. (CA) | 2003-02-19 | — | — | EP | claimed |
| US-20020016342-A1 | Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor | SCOLNICK EDWARD (US) | 2002-02-07 | — | — | US | claimed |
| WO-2001087343-A2 | COMBINATION THERAPY USING COX-2 SELECTIVE INHIBITOR AND THROMBOXANE INHIBITOR AND COMPOSITIONS THEREFOR | MERCK FROSST CANADA & CO. (CA) | 2001-11-22 | — | — | WO | claimed |
| US-6245797-B1 | ADMINISTERING MIXTURE OF ENZYME INHIBITORS | MERCK & CO., INC. | 2001-06-12 | — | — | US | claimed |
| EP-1061908-A1 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | Merck & Co., Inc. (US) | 2000-12-27 | — | — | EP | claimed |
| EP-1024696-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIO- AND CEREBROVASCULAR DISEASE | Merck & Co., Inc. (US) | 2000-08-09 | — | — | EP | claimed |
| WO-1999045913-A1 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 1999-09-16 | — | — | WO | claimed |
| WO-1999020110-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIO- AND CEREBROVASCULAR DISEASE | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | claimed |
| US-20090197833-A1 | Silicon Containing Compounds Having Selective Cox-2 Inhibitory Activity and Methods of Making and Using the Same | ENGLEBIENNE & ASSOCIATES (BE) | 2009-08-06 | — | — | US | disclosed |
| US-20090197833-A1 | Silicon Containing Compounds Having Selective Cox-2 Inhibitory Activity and Methods of Making and Using the Same | ENGLEBIENNE & ASSOCIATES (BE) | 2009-08-06 | — | — | US | disclosed |
| US-20090192211-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | CHEN YING-NAN PAN | 2009-07-30 | — | — | US | disclosed |
| US-20090192211-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | CHEN YING-NAN PAN | 2009-07-30 | — | — | US | disclosed |
| WO-2000018352-A2 | A METHOD FOR TREATING INFLAMMATORY DISEASES BY ADMINISTERING A THROMBIN INHIBITOR | MERCK & CO., INC. (US) | 2000-04-06 | — | — | WO | disclosed |
| WO-1999059635-A1 | USE OF A COX-2 INHIBITOR AND A NK-1 RECEPTOR ANTAGONIST FOR TREATING INFLAMMATION | MERCK SHARP & DOHME LIMITED (GB) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999045913-A1 | COMBINATION THERAPY AND COMPOSITION FOR ACUTE CORONARY ISCHEMIC SYNDROME AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999044640-A1 | COMBINATION OF A SELECTIVE NMDA NR2B ANTAGONIST AND A COX-2 INHIBITOR | MERCK SHARP & DOHME LIMITED (GB) | 1999-09-10 | — | — | WO | disclosed |
| WO-1999020110-A1 | COMBINATION THERAPY FOR REDUCING THE RISKS ASSOCIATED WITH CARDIO- AND CEREBROVASCULAR DISEASE | MERCK & CO., INC. (US) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192211-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | HDAC2, HDAC9, HDAC1 | PTGS2 6/4885PTGS1 13/4885 |
| US-20040097573-A1 | Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation | PTGS1, PTGS2, PTGES2 | PTGS2 2/4885PTGS1 1/4885 |
| US-20090197833-A1 | Silicon Containing Compounds Having Selective Cox-2 Inhibitory Activity and Methods of Making and Using the Same | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885 |
| US-20020016342-A1 | Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor | PTGES2, PTGS2, PTGER1 | PTGS2 2/4885PTGS1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.